What Is MT-2? Research Evidence & Profile

What Is Melanotan II (MT-2)?

Melanotan II (MT-2) is a peptide entry commonly identified by the Melanotan II and MT-2 names. This page identifies the material as Melanotan II (MT-2), with amino acid count 7; synonyms MT-2. The Melanotan II (MT-2) identifiers distinguish this catalogue entry from similarly named compounds, fragments, modified analogues, and multi-component formulations.

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Evidence at a Glance

1ClinicalTrials.gov query records

243PubMed query records

6Selected publications shown

Sources: ClinicalTrials.gov query · PubMed query · Retrieved 2026-10-06

Mechanism & Pharmacology

The research record for Melanotan II (MT-2) is organized around melanocortin receptor research, peptide ligand profiling, signal-response studies, and analytical peptide workflows. For Melanotan II (MT-2), those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome.

Mechanistic or pathway language defines a research scope. It does not establish that a catalogue product produces a clinical effect.

Clinical Development

Selected exact-query registry records are shown below. Desktop displays up to six; mobile displays up to three.

NCT ID / Study	Phase	Status	Context	Last registry update
NCT07437560Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo	Phase 2	Recruiting	NonSegmental Vitiligo, Nonsegmental Vitiligo (Stable)	2026-02-27

Source: ClinicalTrials.gov search · Retrieved 2026-10-06

Selected Literature6 important records shown

Selected Literature

Selected PubMed record

Melanotan II: a possible cause of renal infarction: review of the literature and case report.

CEN case reports · 2020 May

PMID 31953620

Selected PubMed record

Melanotan-II reverses memory impairment induced by a short-term HF diet.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023 Sep

PMID 37478579

Selected PubMed record

Melanotan II User Experience: A Qualitative Study of Online Discussion Forums.

Dermatology (Basel, Switzerland) · 2021

PMID 34464955

Selected PubMed record

CLIPSing Melanotan-II to Discover Multiple Functionally Selective hMCR Agonists.

Journal of medicinal chemistry · 2022 Mar 10

PMID 35188390

Selected PubMed record

Melanotan-II reverses autistic features in a maternal immune activation mouse model of autism.

PloS one · 2019

PMID 30629642

Selected PubMed record

Discovery and development of novel melanogenic drugs. Melanotan-I and -II.

Pharmaceutical biotechnology · 1998

PMID 9760697

Source: PubMed search results · Retrieved 2026-10-06

Identity & ChemistryProduct-form fields

Identity & Chemistry

Compound / Blend: Melanotan II (MT-2)
Available Specifications: 10mg
Pack Format: 10 Vials
CAS Number: 121062-08-6
Molecular Formula: C50H69N15O9
Molecular Weight: 1024.18 g/mol
Amino Acid Count: 7
Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2
Synonyms: MT-2
Physical Form: Lyophilized powder

Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Source: PubChem CID 92432 · Product form must still be matched to the catalogue and batch record.

Research Tools for Melanotan II (MT-2)

Review the selected registry records and open the module-level ClinicalTrials.gov query for the current result set.

Open Clinical Development

Use the complete NOVABIO documentation library to review currently available batch records.

Open Lab Results & COA

Storage & Laboratory HandlingDocumentation-led controls

Storage & Laboratory Handling

Confirm the exact material form, lot, supplied state and storage statement from the product label and corresponding batch documentation. Do not infer handling conditions from a different compound, strength or external clinical publication.

Regulatory Status

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Source: FDA Drugs@FDA · Checked 2026-10-06

Authoritative Data Summary

Melanotan II (MT-2) Research Summary

Identity

Melanotan II (MT-2); specifications: 10mg. Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation.

Mechanism

Evidence

1 registry records and 243 PubMed records were returned by the displayed query on 2026-10-06; counts are not quality ratings.

Regulatory context

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Melanotan II (MT-2) is represented here by the catalogue identity Melanotan II (MT-2). Identity fields describe the named catalogue record and must not be generalized to a different salt, counter-ion, hydrate or formulation. The product record lists 10mg as the currently available specifications. The research context is organized around this product-specific scope: The research record for Melanotan II (MT-2) is organized around melanocortin receptor research, peptide ligand profiling, signal-response studies, and analytical peptide workflows. For Melanotan II (MT-2), those subjects define the literature and analytical context of this specific research peptide; they do not establish a clinical indication, administration route, or expected outcome. The synchronized searches returned 1 ClinicalTrials.gov records and 243 PubMed records for the displayed query. A registry count includes records with different designs, statuses and populations, while a publication count can include reviews, preclinical work and unrelated uses of a shared abbreviation; neither count is a quality score. For regulatory interpretation, FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval. Clinical findings apply only to the studied drug product, formulation, population and protocol. NOVABIO product specifications and batch documentation are separate catalogue records and do not inherit clinical outcomes from external studies. This profile supports identity checking, source tracing and laboratory record review; it does not certify a batch, recommend treatment, provide dosing instructions or replace current official labeling and professional judgment.

Sources: PubMed · ClinicalTrials.gov · FDA · NOVABIO product record

FAQ4 evidence-bounded answers

Melanotan II (MT-2) FAQ

What is Melanotan II (MT-2)?

What research records are indexed for Melanotan II (MT-2)?

The synchronized query returned 1 ClinicalTrials.gov records and 243 PubMed records on 2026-10-06; review the linked searches because counts and record status can change.

Is Melanotan II (MT-2) FDA approved?

FDA status must be checked by exact drug product, formulation and indication; catalogue availability does not establish approval.

Does this page provide dosing guidance?

No. This research profile provides identity, evidence, chemistry, regulatory and documentation context without dosing or treatment instructions.

Sources, Methodology & Last Verified

Official sources: ClinicalTrials.gov, NCBI PubMed, FDA, available PubChem records, and NOVABIO product and COA records.
Query retrieved: 2026-10-06T12:08:49Z
Inclusion: Exact identity terms and traceable registry, publication, chemistry, regulatory or catalogue fields.
Limitations: Search counts can include mixed evidence types and shared-name records; individual records require direct review.
Prepared by: NOVABIO Research
Reviewed date: 2026-10-06
Editorial methodology: How NOVABIO builds Research Profiles
Corrections contact: Contact NOVABIO with the page URL and source record.